G6PC3

Across TCGA pan-cancer cohorts, G6PC3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated G6PC3 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher G6PC3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated G6PC3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where G6PC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.649	0.829	.003	43	view →
LSCC	OS	Tertile	III,IV	0.938	0.500	.014	15	view →
UCEC	DFS	Quartile	All	0.855	1.000	.018	12	view →
GBM	DFS	Median	All	0.644	0.829	.007	4	view →
CCRCC	DFS	Tertile	All	0.862	0.633	.028	4	view →
LUAD	DFS	Median	All	0.879	1.000	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

G6PC3–PDAC (DFS)

Open the PDAC breakdown →